Halo Labs commercializes biopharmaceutical analysis instrumentation. The company was named Philadelphia Life Science Startup of 2012. Halo Labs is venture-backed by Research Corporation Technologies, BroadOak Capital Partners, BioAdvance, and the Ben Franklin Technology Partners. Halo Labs' flagship product, the Horizon®, enables for the first time high-throughput, low-volume subvisible particle analysis and is funded by prestigious small business grants from NIST and the FDA.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/27/18 | $5,600,000 | Series B |
Research Corporation Technologies | undisclosed |
| 04/06/20 | $12,000,000 | Series B-1 |
BioAdvance BroadOak Capital Partners Paul McEwan Research Corporation Technologies | undisclosed |
| 07/11/22 | $6,000,000 | Series C |
Agilent Technologies BioAdvance Broad Oak Capital Partners Research Corporation Technologies | undisclosed |
